LXEO — Lexeo Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1907108 ·
Last close
$2.86
Market Cap
$234.24M
52W High
$10.99
52W Low
$2.55
ADV30
2,615,594
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -40,399,000 | -38,300,000 | 243,916,000 | 90,219,000 | 27,225,000 |
| Jun 2026 | 0 | — | -28,020,000 | -25,867,000 | 254,898,000 | 92,834,000 | 19,837,000 |
| Mar 2026 | 0 | — | -22,333,000 | -20,196,000 | 250,356,000 | 71,768,000 | 18,859,000 |
| Dec 2025 | 0 | — | -23,116,000 | -20,919,000 | 268,688,000 | 63,000,000 | 22,019,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-88,367,000
Investing CF
$-24,954,000
Financing CF
$170,675,000
CapEx
$-331,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.15
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-426,197,000
Inventory
—
Receivables
—
ST Investments
$118,869,000
EBIT TTM
$-87,106,000
Pretax Income TTM
$-87,265,000
Interest Exp TTM
$159,000
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -109,257,000 | -99,961,000 | 268,688,000 | 22,019,000 | 246,669,000 | -98,561,000 |
| Dec 2024 | 0 | -105,766,000 | -98,333,000 | 146,942,000 | 30,100,000 | 116,842,000 | -81,151,000 |
| Dec 2023 | 0 | -68,513,000 | -66,394,000 | 139,807,000 | 26,272,000 | 113,535,000 | -59,496,000 |
| Dec 2022 | 654,000 | -60,509,000 | -59,277,000 | 97,076,000 | 210,030,000 | -112,954,000 | -54,560,000 |
TTM Snapshot
Revenues TTM
$7,976,000
NetIncome TTM
$-87,265,000
OpCashFlow TTM
—
Assets (Latest)
$254,898,000
Forward EPS
$-1.37
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $2.95 · call volume: 56 · put volume: 104Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PROK | PROKIDNEY CORP. | $229.87M | $1.10 | — |
| PLX | Protalix BioTherapeutics, Inc. | $242.84M | $2.88 | — |
| IPSC | Century Therapeutics, Inc. | $248.79M | $1.37 | — |
| CABA | Cabaletta Bio, Inc. | $220.03M | $1.02 | — |
| OCGN | Ocugen, Inc. | $256.75M | $0.76 | — |
News headlines (Yahoo Finance, 1h cache)
Lexeo Therapeutics Q3 Earnings Call Highlights
2026-11-16 16:15 · Yahoo
Lexeo Therapeutics shares surge 25% on interim data for LX2020 gene therapy
2026-11-16 14:01 · Yahoo
Lexeo Therapeutics Reports LX2020 Gene Therapy Trial Data and Outlines Potential FDA Accelerated Approval Pathway
2026-11-16 13:47 · Yahoo
Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
2026-11-16 12:00 · Yahoo
Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
2026-11-15 12:00 · Yahoo
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
2026-11-02 12:00 · Yahoo
Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout
2026-10-25 14:02 · Yahoo
Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy
2026-10-24 07:02 · Yahoo
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
2026-10-19 11:00 · Yahoo
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
2026-10-08 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.